Table 1 Clinicopathologic characteristics of patients according to breast cancer phenotype

Age (years)

0.012

  ≤50

428 (59.4)

173 (57.1)

113 (66.9)

32 (45.1)

110 (61.8)

  >50

293 (40.6)

130 (42.9)

56 (33.1)

39 (54.9)

68 (38.2)

Histologic grade

<0.001

  I/II

485 (67.3)

275 (90.8)

112 (66.3)

37 (52.1)

61 (34.3)

  III

236 (32.7)

28 (9.2)

57 (33.7)

34 (47.9)

117 (65.7)

Tumor stage

0.002

  T1

355 (49.2)

169 (55.8)

86 (50.9)

32 (45.1)

68 (38.2)

  T2/T3

366 (50.8)

134 (44.2)

83 (49.1)

39 (54.9)

110 (61.8)

Nodal metastasis

0.162

  Absent

427 (59.2)

173 (57.1)

93 (55.0)

44 (62.0)

117 (65.7)

  Present

294 (40.8)

130 (42.9)

76 (45.0)

27 (38.0)

61 (34.3)

Estrogen receptor status

<0.001

  Negative

259 (35.9)

5 (1.7)

5 (3.0)

71 (100.0)

178 (100.0)

  Positive

462 (64.1)

298 (98.3)

164 (97.0)

0 (0.0)

0 (0.0)

Progesterone receptor status

<0.001

  Negative

347 (48.1)

50 (16.5)

48 (28.4)

71 (100.0)

178 (100.0)

  Positive

374 (51.9)

253 (83.5)

121 (71.6)

0 (0.0)

0 (0.0)

HER-2 status

<0.001

  Negative

565 (78.4)

303 (100.0)

84 (49.5)

0 (0.0)

178 (100.0)

  Positive

156 (21.6)

0 (0.0)

85 (50.3)

71 (100.0)

0 (0.0)

Ki-67 LI (%)

<0.001

  ≤14

409 (56.7)

303 (100.0)

49 (29.0)

29 (40.8)

28 (15.7)

  >14

312 (43.3)

0 (0.0)

120 (71.0)

42 (59.2)

150 (84.3)

Tumor recurrence

63 (8.7)

15 (5.0)

13 (7.7)

11 (15.5)

24 (13.5)

0.002

No. of patient deaths

61 (8.5)

13 (4.3)

13 (7.7)

11 (15.5)

24 (13.5)

0.001

Duration of clinical follow-up (months, mean ± SD)

69.9 ± 31.2

71.9 ± 29.0

70.0 ± 30.1

66.1 ± 34.9

68.1 ± 34.1

0.419